CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
What's Your Reaction?
